Part VI: Three antiviral regimens
6.1-Purpose of study
Evaluate the effect and safety of three antiviral regimens in treating pneumonia patients infected with the common or novel coronavirus.
6.2-Clinical trial information points
The clinical trial recruits 120 patients in total and divides them into three groups, with 40 in each group. The first group (Group A) is administered ribavirin+interferon α1b; the second group (Group B) is administered lopinavir/ritonavir+interferon α1b; the third group (Group C) is administered ribavirin+lopinavir/ritonavir+interferon α1b.
Part VII: Glucocorticoid (methylprednisolone)
7.1-Purpose of study
Evaluate the effect and safety of the glucocorticoid in treating novel coronavirus infection and explore the optimal treatment mode.
7.2-Clinical trial information points
Intervention group dosing regimen: lopinavir/ritonavir tablets (with each tablet containing 200mg lopinavir and 50mg ritonavir), twice daily, 2 tablets per time; α-interferon aerosol inhalation (5 million U per time, added with 2ml sterile water for injection), twice daily; methylprednisolone intravenous injection, 1~2mg/kg·d, for 5 days;
Control group dosing regimen: lopinavir/ritonavir tablets (with each tablet containing 200mg lopinavir and 50mg ritonavir), twice daily, 2 tablets per time; α-interferon aerosol inhalation (5 million U per time, added with 2ml sterile water for injection), twice daily, without using glucocorticoid.
Part VIII: Xuebijing Injection
8.1-Purpose of study
Evaluate the improvement of the pneumonia severity index (PSI) by Xuebijing and the influence thereof on the 28-day prognosis.
8.2-Clinical trial information points
According to the registration information, the trial has two trial groups, with one administered Xuebijing Injection and the other one receiving the conventional treatment.
Part IX: Combination therapy of lopinavir/ritonavir and interferon α2b
9.1-Purpose of study
Evaluate the effect and safety of the combination therapy of lopinavir/ritonavir and interferon α2b in treating adult inpatients infected with novel coronavirus compared to the standard treatment.
9.2-Clinical trial information points
According to the clinical trial registration information, the trial group will be administered lopinavir/ritonavir tablets (each containing 200mg lopinavir and 50mg ritonavir), twice daily, and 2 tablets per time, and also interferon α2b, while the control group will receive the conventional treatment.
Part X: Remdesivir
According to the news of the China-Japan Friendship Hospital on the noon of Feb. 2, 2020, the China-Japan Friendship Hospital will lead the clinical study of treating 2019-nCoV with remdesivir in 2019-nCoV-affected Wuhan.
10.1-Purpose of study
The purpose of study according to the screenshot on the internet is a randomized, double-blind, controlled, multicenter clinical trial to evaluate the effect and safety of remdesivir in patients infected with 2019-nCoV.
The following screenshot taken from the database of the NMPA shows the registration information of remdesivir. According to it, r...










(All Rights Reserved)